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Problem: Menstrual disorders, reduced fertility and sexual problems seem to be more frequent in women with epilepsy than
in the general population. Most investigations concerning menstrual disturbances in epilepsy patients, however, are small and
based on selected materials. We therefore wanted to investigate the frequency of menstrual disturbances in a large, unselected
population of epilepsy patients.
Methods: A retrospective, questionnaire study of a cohort of female outpatients, aged 18–45 was conducted. Each patient chose
a close female friend who served as control, to optimise matching regarding age and lifestyle.
Results: Answers were received from 265 patients and 142 controls. Menstrual disturbances were more frequent in patients with
epilepsy (48.0%) than in controls (30.7%) (P = 0.004). Menstrual disturbances were more frequent in patients on polytherapy
versus monotherapy (P = 0.049) and more frequent in patients with high seizure frequency (>5 seizures/year) compared to
patients with a lower seizure frequency or those seizure free (P = 0.006). The frequency of menstrual disturbances was higher
in patients on valproate compared to carbamazepine monotherapy (P = 0.045).
Conclusion: This investigation confirms that women with epilepsy have an increased frequency of menstrual disturbances
compared to women without epilepsy. In women with high seizure frequency and in those on polytherapy, the frequency
of menstrual disturbances are further increased. The highest frequency of menstrual disturbances occurred in women using
valproate.
© 2003 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
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INTRODUCTION
Several reports have demonstrated an increased fre-
quency of menstrual disturbances, fertility prob-
lems, polycystic ovaries and hormonal changes in
women with epilepsy1–5. This can be due to either
the epilepsy itself, or the use of antiepileptic drugs
(AEDs). In particular, epileptic activity in the tempo-
ral lobes seems to be related to endocrine effects2, 6.
On the other hand, several AEDs are known to
interfere with mechanisms involved in the regula-
tion of the hypothalamic–pituitary axis5, 10–12, and
AEDs may also affect the metabolism of steroid hor-
mones and binding proteins13. Recently, valproate
has been associated with the development of polycys-
tic ovaries and hyperandrogenism in female epilepsy
patients11, 12, 14, 15. These observations have been
questioned by some authors, claiming that the studies
were done in small and selected patient populations16.
An old investigation of healthy women without
epilepsy showed menstrual disturbances in 27%17. In
a study of normal women of reproductive age who
had not sought treatment for menstrual disturbances,
infertility or hirsutism, 18% were found to have ir-
regular cycles18. Very few population-based studies
on the frequency of menstrual disturbances in women
with epilepsy have been performed, and those who
exist are based on small and selected patient groups
(ranging from 50 to 101 patients) without comparison
with matched controls3, 19.
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We wanted to investigate the frequency of men-
strual disturbances in a larger group of female epilepsy
out-patients and compare the results with those of a
matched control population. We also wanted to study
factors that might affect reproductive endocrine func-
tions, such as seizure type and frequency, AEDs, age
of epilepsy debut and body mass index (BMI).
METHODS
The study was retrospective and questionnaire-based.
The intention was to investigate a non-selected group
of epilepsy patients. The questionnaires were therefore
sent to a cohort of 500 female out-patients recruited
from three different Norwegian hospitals; Rikshospi-
talet, Ullevål University Hospital and Telemark Hos-
pital. The patients were between 18 and 45 years of
age. The questionnaire contained questions regarding
the menstrual cycle, fertility, reproductive health, con-
ception control and the epilepsy itself. Each patient
received two questionnaires; one for themselves and
one for a close friend without epilepsy. The friends
served as a non-epileptic control group. This was done
to optimise matching, regarding age and lifestyle.
The study was approved by the Regional Ethical
Committee.
Table 1: Summary of clinical findings.
Parameter Controls (n = 142) Patients (n = 265), Patients (n = 45),
responders non-responders
Age, years (mean, SD) 32.0 (7.66) 32.3 (6.99) 30.7 (7.08)
BMI (mean) 24.1 (4.23) 24.3 (4.78)
Age of menarche, years (mean, SD) 13.0 (1.46) 13.1 (1.50)
Children/woman (mean) 1.11∗ (1.15) 0.85 (1.07)
Epilepsy debut age (mean, SD) 16.4∗ (11.1) 13.5 (8.25)
Type of epilepsy
Partial (%) 59.9 53.3
Generalized (%) 35.9 46.7
Unclassified (%) 4.2 0
Seizure frequency (years)
Seizure free (%) 51.3 46.7
1–5 seizures (%) 15.5 11.1
>5 seizures (%) 25.3 22.2
No information (%) 7.9 20.2
Medication
Monotherapy (%) 60.0 57.8
CBZ (%) 48.4 53.9
LTG (%) 21.4 7.7
VPA (%) 13.2 11.5
Others (%) 17.0 26.9
Polytherapy (%) 23.0 24.4
No medication (%) 13.6 17.8
No information (%) 3.4 0
∗ P < 0.05.
The epilepsy type was classified according to the
classification system of the International League
Against Epilepsy20. Menstrual disturbances were de-
fined according to Polson et al.18, as periods of less
than 22 days or more than 35 days, or bleeding dura-
tion of more than 8 days, or a variation of more than
4 days between two consecutive menstrual periods
within the last 6 months.
Statistical analyses
The Chi-square test and Fisher’s exact test were used
for analyses of categorical data. Independent sample
t-test was used for analyses of continues data. A value
of P < 0.05 (two tailed) was considered significant.
RESULTS
Answers were received from 265 patients and 142 con-
trols. Age, BMI and menarche age were equal between
patients and controls (Table 1). In the epilepsy group,
59.9% had partial and 35.9% generalised epilepsy. The
epilepsy type could not be defined in 4.2% of the pa-
tients. 51.3% of the patients were seizure-free during
the last 12 months, 15.5% had 1–5 seizures and 25.3%
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Fig. 1: (A) Menstrual disturbances in patients (left column)
and controls (right column). (B ) Menstrual disturbances in
patients on monotherapy (left column) and polytherapy
(right column). (C) Menstrual disturbances in seizure-free
patients (left column), patients having 1–5 seizures/year
(middle column) and patients having more than
5 seizures/year (right column), ∗P<0.05.
had more than 5 seizures during the last 12 months.
7.9% of the patients did not give sufficient informa-
tion about seizure frequency. 60% were on monother-
apy and 23.0% on polytherapy, while 13.6% did not
use any medication (Table 1).
In the epilepsy group, 48.0% (94/196) had menstrual
disturbances, compared to 30.7% (31/101) in the con-
trol group (P = 0.004) (Fig. 1). In both groups, pa-
tients on contraceptive pills, using hormone IUD or
who were pregnant were excluded from the analysis
regarding menstrual irregularities.
Patients having more than 5 seizures during the last
year had significantly more menstrual disturbances
than seizure-free patients; 66% (31/47) compared to
38.9% (38/98) (P = 0.006) (Fig. 1). There was no
difference in frequency of menstrual disturbances be-
tween patients with primary generalised (50.7%) ver-
sus partial epilepsy (47.8%) (Fig. 2).
In the monotherapy group, 45.1% (55/122) had men-
strual disturbances compared to 62.2% (28/45) in the
polytherapy group (P = 0.049) (Fig. 1). Menstrual
disturbances were significantly more frequent in all
valproate treated patients (62%, n = 21) compared to
all carbamazepine treated patients (37.2%, n = 59)
(P = 0.045, Fig. 2). The frequency of menstrual dis-
turbances was the same in patients using valproate for
generalised epilepsy (63.6%, n = 11) compared to
patients using valproate for partial epilepsy (55.5%,
n = 9) (P = 0.67). The frequency of menstrual dis-
turbances was also the same in patients using carba-
mazepine for generalised epilepsy (45.5%, n = 22)
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Fig. 2: (A) Menstrual disturbances in patients with primary
generalized epilepsy (50.7%) and partial epilepsy (47.8%).
(B ) Menstrual disturbances in patients on valproate (62%)
and carbamazepine (37.2%) (P=0.045). (C ) Menstrual
disturbances in patients on valproate, having primary
generalized epilepsy (63.6%) and partial epilepsy (55.5%).
(D) Menstrual disturbances in patients on carbamazepine,
having primary generalized epilepsy (45.5%) and partial
epilepsy (36.4%), ∗P< 0.05.
as in patients using carbamazepine for partial epilepsy
(36.4%, n = 33) (P = 0.22) (Fig. 2). Valproate treated
patients had a higher frequency of menstrual distur-
bances than patients on all other drugs in monotherapy
taken together, but this difference was not statistically
significant (62% (n = 21) vs. 41.6% (n = 101); P =
0.072). Women with epilepsy had significantly fewer
children than controls. Mean number of children per
woman in the patient group was 0.85 versus 1.11 in
the control group (P = 0.029) (Table 1).
There was no significant correlation between age of
debut of epilepsy or how many years the patient had
been suffering from epilepsy, and the frequency of
menstrual disorders.
BMI was slightly higher in patients with menstrual
disorders than in patients without menstrual problems
(25.4 vs. 24.2), and in patients on polytherapy (25.9)
compared to monotherapy (24.3), but the differences
were not significant (P = 0.10 and 0.14, respectively).
BMI in the valproate group (24.9) was higher than
in patients treated with other drugs in monotherapy
(23.9), but again the difference was not significant
(P = 0.26).
A major problem with all retrospective, question-
naire-based studies is the responder rate, which was
53% in our study (265/500). We managed, however,
to find 45 of the non-responders from one of the hos-
pitals (Rikshospitalet). Medical records from these
non-responders were reviewed and information anal-
ysed as for the patients (Table 1). The only param-
eter that differed from the responders, was age of
epilepsy debut that was about 3 years lower in the
non-responder group.
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DISCUSSION
This is the first population based study of menstrual
disturbances in women with epilepsy where the results
are compared to a matched control group of women
without epilepsy. The main finding is that women with
epilepsy experience a marked increase in menstrual
disturbances. Thus, although menstrual disturbances
are common in the general population17, 18, our study
clearly emphasises the relation between epilepsy and
menstrual disturbances. Our review of the medical
records from non-responders did not reveal any ma-
jor differences compared to women who answered the
questionnaire. We therefore consider answers given in
our study to be representative for women with epilepsy
in our population in general.
The main question when trying to explain the in-
creased frequency of menstrual disturbances in women
with epilepsy, is whether this is caused by the epilepsy
itself or by the treatment. Epileptic activity is shown
to induce hormonal disturbances in both animals7–9
and humans2, 6, 21. In our study, we found that women
with more than 5 seizures during the last year had an
increased risk of menstrual disturbances compared to
seizure-free patients, while there was no difference be-
tween patients with partial versus generalised epilepsy.
This implies that seizure frequency is more impor-
tant than epilepsy type. However, the use of polyther-
apy was also significantly higher in patients with high
seizure frequency (P < 0.001) and women on poly-
therapy had a higher frequency of menstrual disor-
ders than women on monotherapy (P = 0.049). This
makes it difficult to decide with certainty whether it is
the epilepsy itself or the heavy medication that is of
greatest importance for the development of the men-
strual disorder.
The lack of difference in frequency of menstrual dis-
turbances between women with partial compared to
generalised epilepsy may be due to the fact that the
different epilepsy types were treated differently. This
does not seem to be the case. When looking at patients
on valproate monotherapy, there was no difference re-
garding menstrual disturbances between those having
partial or generalised epilepsy. Similar findings were
done in carbamazepine treated women with no differ-
ence in menstrual disturbances in those treated for gen-
eralised or partial epilepsy. There were, however, sig-
nificantly more menstrual problems among all women
treated with valproate versus all women treated with
carbamazepine. This indicates that the type of epilepsy
is of less importance regarding development of men-
strual disturbances.
Former studies22 have shown an increased risk
of anovulatory cycles in women with generalised
epilepsy, particularly those on valproate. In the pa-
tients receiving phenobarbital and lamotrigine the
epilepsy type had no significant effect. The seizure
frequency was not taken into consideration in that
study. In our study, seizure rate was a significant factor
in increasing the frequency of menstrual disturbances.
Other studies have shown increased frequency of en-
docrine dysfunction in patients with temporal lobe
epilepsy. Because our study was a blinded question-
naire study we did not have enough detailed informa-
tion to code the partial epilepsies into subgroups.
AED treatment has been found by several authors to
induce menstrual disturbances11, 12, 15, 23. In our study,
the relationship between polytherapy and menstrual
disturbances was pronounced. We found that as many
as 62.2% of patients on polytherapy had menstrual
disturbances compared to 45.1% in the monotherapy
group.
Type of medication has also been considered as
having an effect on menstrual regularity. Previous
studies have shown endocrine side-effects when
using specific AEDs in monotherapy, especially
valproate11, 12, 14, 15, 23–25. Our study supports these
findings. We found that women using valproate in
monotherapy are significantly more likely to have
a menstrual disturbance than women taking car-
bamazepine irrespective of the epilepsy type, as
discussed above. When comparing valproate to the
group of all other AEDs in monotherapy, there was
no significant difference in menstrual disturbances.
The reason for this might be that lamotrigine is
widely used in Norway, especially in women having
menstrual disturbances. In our material, 13 of 21 pa-
tients using lamotrigine had menstrual disturbances.
However, four of these women had changed medica-
tion from valproate to lamotrigine due to menstrual
irregularities, and seven reported that the menstrual
disturbances started before the use of AEDs. Thus, in
only two patients menstrual disturbances started after
the introduction of lamotrigine.
It has been claimed that the endocrine effects of val-
proate is caused by an increase in BMI16. In our study
we found only a slightly higher BMI in patients treated
with valproate than patients on all other drugs, but
the difference was not significant. This weigh against
BMI as a major factor in the development of menstrual
disturbances in women treated with valproate.
In our study the epilepsy patients had fewer chil-
dren than the control group (0.85 vs. 1.11, P < 0.05).
The reason for this is complex. Seizure-free patients
had significantly higher number of children than pa-
tients with more than 5 seizures a year (1.01 vs. 0.53
children, P = 0.001). Not having children can there-
fore be a deliberate choice in women with frequent
seizures. For some of the women, epilepsy was only
one symptom of a more complex neurological or med-
ical disease. Some of these women have brain injuries
or inherited diseases such as neurofibromatosis that
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makes pregnancies unfavourable. However, we can not
rule out the possibility that reduced fertility could be
due to epileptic activity itself as more seizures also
were associated with a higher frequency of menstrual
disturbances. Alternatively the use of AEDs inducing
endocrine dysfunction could be responsible.
In conclusion, women with epilepsy have an in-
creased frequency of menstrual disorders compared
to women without epilepsy. Menstrual disturbances
are significantly more frequent in women with high
seizure frequency and in women on polytherapy. Men-
strual disturbances are significantly more frequent
in women on valproate compared to carbamazepine
monotherapy. The reason for the increased risk for
menstrual disturbances in women with epilepsy is
complex, and probably caused by a combination of the
epileptic activity and the antiepileptic medication.
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